Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07499362 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 3 to 4v7
  2. 2 versions Re-verified since Jul 8, 2026, no change to tracked fieldsv5-v6
  3. Study sites: 2 to 3v4
  4. Study sites: 1 to 2v3
  5. Recruitment opened Primary and study completion dates: Dec 7, 2029 to Nov 22, 2029 · Start date changed from estimate of Apr 27, 2026 to Mar 26, 2026 · Study site revisedv2 Show 3 more changesShow less
    • Primary and study completion dates: Dec 7, 2029 to Nov 22, 2029
    • Start date changed from estimate of Apr 27, 2026 to Mar 26, 2026
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck KGaA
43 trials monitored
See 4 trials at risk
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
Trial Details
NCT Number NCT07499362
Lead Sponsor Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Tenosynovial Giant Cell Tumor
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov